MediWound Ltd. Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care

Reuters

2025/05/21

<a href="https://laohu8.com/S/MDWD">MediWound Ltd.</a> Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care

MediWound Ltd. recently presented its advancements in next-generation enzymatic therapeutics for non-surgical tissue repair. The company highlighted two key products: EscharEx® and NexoBrid®. EscharEx® is an investigational therapy aimed at debridement of chronic wounds, targeting a $2.5 billion U.S. market, with ongoing Phase 3 trials. NexoBrid®, already approved in the U.S., EU, and Japan, focuses on eschar removal for severe burns and has generated $20 million in revenue in 2024. MediWound also underscored its solid balance sheet with $39 million in cash and strategic global collaborations to support its efforts. The company's cGMP certified manufacturing facility is set to scale up to meet global demand by the end of 2025. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2537938643"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2537938643\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2537938643?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-21 20:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2537938643","market":"nz","top_or_hot":-1,"title":"MediWound Ltd. Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDWD\">MediWound Ltd.</a> Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediWound Ltd. recently presented its advancements in next-generation enzymatic therapeutics for non-surgical tissue repair. The company highlighted two key products: EscharEx® and NexoBrid®. EscharEx® is an investigational therapy aimed at debridement of chronic wounds, targeting a $2.5 billion U.S. market, with ongoing Phase 3 trials. NexoBrid®, already approved in the U.S., EU, and Japan, focuses on eschar removal for severe burns and has generated $20 million in revenue in 2024. MediWound also underscored its solid balance sheet with $39 million in cash and strategic global collaborations to support its efforts. The company's cGMP certified manufacturing facility is set to scale up to meet global demand by the end of 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MediWound Ltd. Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMediWound Ltd. Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-21 20:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MDWD\">MediWound Ltd.</a> Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        MediWound Ltd. recently presented its advancements in next-generation enzymatic therapeutics for non-surgical tissue repair. The company highlighted two key products: EscharEx® and NexoBrid®. EscharEx® is an investigational therapy aimed at debridement of chronic wounds, targeting a $2.5 billion U.S. market, with ongoing Phase 3 trials. NexoBrid®, already approved in the U.S., EU, and Japan, focuses on eschar removal for severe burns and has generated $20 million in revenue in 2024. MediWound also underscored its solid balance sheet with $39 million in cash and strategic global collaborations to support its efforts. The company's cGMP certified manufacturing facility is set to scale up to meet global demand by the end of 2025. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDWD","symbol_name":"MediWound Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nNDL9F9qbn:1","article_id":"2537938643","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2537938643","pubTimestamp":1747830310,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"MediWound Ltd. recently presented its advancements in next-generation enzymatic therapeutics for non-surgical tissue repair. The company highlighted two key products: EscharEx and NexoBrid. EscharEx is an investigational therapy aimed at debridement of chronic wounds, targeting a $2.5 billion U.S. market, with ongoing Phase 3 trials. NexoBrid, already approved in the U.S., EU, and Japan, focuses on eschar removal for severe burns and has generated $20 million in revenue in 2024. MediWound also underscored its solid balance sheet with $39 million in cash and strategic global collaborations to support its efforts. The company's cGMP certified manufacturing facility is set to scale up to meet global demand by the end of 2025. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDWD":"MediWound Ltd.","BK4007":"制药"},"translate_title":"MediWound Ltd.推出用于组织修复和伤口护理的下一代酶疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDWD":0.9},"content_text":"MediWound Ltd. Unveils Presentation on Next-Gen Enzymatic Therapies for Tissue Repair and Wound Care\n    \n\n        MediWound Ltd. recently presented its advancements in next-generation enzymatic therapeutics for non-surgical tissue repair. The company highlighted two key products: EscharEx® and NexoBrid®. EscharEx® is an investigational therapy aimed at debridement of chronic wounds, targeting a $2.5 billion U.S. market, with ongoing Phase 3 trials. NexoBrid®, already approved in the U.S., EU, and Japan, focuses on eschar removal for severe burns and has generated $20 million in revenue in 2024. MediWound also underscored its solid balance sheet with $39 million in cash and strategic global collaborations to support its efforts. The company's cGMP certified manufacturing facility is set to scale up to meet global demand by the end of 2025. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediWound Ltd. published the original content used to generate this news brief on May 21, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}